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Botulinum neurotoxins (BoNTs), the causative agent of human botulism, are the most potent nat-
urally occurring toxins known. BoNT/A1, the most studied BoNT, is also used as an important bio-
pharmaceutical. In this study, the biological activity of BoNT/A1 is compared to that of BoNT/A2
using neuronal cell models. The data obtained indicate faster and increased intoxication of neu-
ronal cells by BoNT/A2 than BoNT/A1, and that the mechanism underlying this increased toxicity
is faster and more efﬁcient cell entry that is independent of ganglioside binding. These results
have important implications for the development of new BoNT based therapeutics and BoNT
countermeasures.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Botulinum neurotoxins (BoNTs), the most potent protein toxins
known, cause botulism and are produced by a heterogenous group
of neurotoxigenic bacteria including Clostridium botulinum, and se-
lect strains of Clostridium butyricum and Clostridium baratii [1,2].
Based on their antigenic speciﬁcity, BoNTs are classiﬁed into seven
serotypes (A–G) [2], with BoNT/A, B, E, and F accounting for most
recorded cases of human botulism [1]. BoNTs are important dis-
ease causing agents [1,3], potential bioterrorism agents [4], and
pharmaceuticals for treating neuromuscular disorders and cos-
metic use [5,6].
BoNTs are 150 kDa proteins consisting of a heavy chain (HC,
100 kDa) and a light chain (LC, 50 kDa) linked by a disulﬁde
bond. BoNT intoxication of neuronal cells requires multiple steps
(reviewed in [7]). The C-terminal domain of the HC (HCR/A) binds
dual receptors, ﬁrst a ganglioside on the cell surface and then a
protein receptor upon neurotransmitter vesicle fusion with the
plasma membrane [8]. The toxin–receptor complex then enterslf of the Federation of European Bi
.the neuron via endocytosis (reviewed in [9–11]), and acidiﬁcation
within the endosome leads to a conformational change and forma-
tion of a HC channel in the endocytic vesicle membrane [12,13].
The translocation domain of the HC then conducts the LC through
the HC-channel into the cytosol and the disulﬁde bond linking the
HC and LC is reduced. The released LC refolds to a catalytically
competent conformation within the cytosol [12,13]. LCs are zinc
endopeptidases that cleave and inactivate Soluble N-ethylmalei-
mide Sensitive Fusion Attachment Protein Receptors (SNARE),
which are essential for neurotransmitter release [14–19].
Several subtypes of most BoNT serotypes have been identiﬁed
by nucleotide sequence analysis (reviewed in [20]). BoNT/A has
been divided into ﬁve subtypes (A1–A5) [21–28], but limited
information is available on biological and functional characteris-
tics among BoNT subtypes. Prior analyses of BoNT/A subtypes
include studies using recombinant LC endopeptidases of BoNT/
A1–A4 expressed in Escherichia coli, which indicate that all four
subtypes bind SNAP-25 with similar afﬁnity, but that rLC/A3
and rLC/A4 cleave SNAP-25 signiﬁcantly less efﬁciently than
rLC/A1 and rLC/A2 [29]. Sequence and structural analyses show
that BoNT/A1 and A2 differ by 10% at the amino acid level,
with the greatest difference in the receptor binding domain. Inochemical Societies.
Fig. 1. Sensitivity of RSC cells to BoNT/A2 and A1. (A) 48 h exposure; (B) 4 h exposure; (C) exposure to 150 Units for 1–6 h. Representative Western blots are shown.
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main are highly conserved [21,25]. BoNT/A1 and A2 have signif-
icantly altered monoclonal antibody binding and inhibition
proﬁles by monoclonal antibodies [25], but no differences were
observed in protection against the two subtypes by polyclonal
antisera raised against BoNT/A1 [30].
Of the ﬁve BoNT/A subtypes identiﬁed, BoNT/A1, A2, and A5
have now been puriﬁed [31,32], enabling detailed studies which
are needed to facilitate the increasing use of BoNTs for medicinal
use and to develop effective countermeasures to intoxication by
the various subtypes of BoNTs. A recent report suggests that
BoNT/A2 is more potent than BoNT/A1 in vivo [33]. The data
presented here demonstrate that BoNT/A2 is more potent than
BoNT/A1 in neuronal cells due to faster cell entry.2. Materials and methods
2.1. Botulinum neurotoxins
BoNT/A1, A2, and E were puriﬁed as previously described
[34,32,35]. The speciﬁc activities were determined via the mouse
bioassay [36,37] to be 1.3  108 LD50 Units/mg for BoNT/A1,
4.3  108 Units/mg for BoNT/A2, and 0.76  108 Units/mg for
BoNT/E.
2.2. Reagents
Tissue culture reagents, media, and Western blot supplies were
obtained from Invitrogen (Carlsbad, CA). Neuro-2a cells were pur-
Fig. 2. Cell entry kinetics of BoNT/A2, E, and A1 in RSC cells. RSC cells were exposed
to 500 U BoNT for 6 min, and toosendanin was added as indicated. Representative
Western blots are shown.
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neurons from BrainBits, LLC. CITIFLUOR AF-3 was purchased from
Electron Microscopy Sciences and toosendanin was purchased
from AvaChem Scientiﬁc (San Antonio, TX) with purity conﬁrmed
as described [38]. All other chemicals were obtained from SIGMA.
2.3. Primary rat spinal cord (RSC) cells assay
The preparation of spinal cord cells and toxin assays were pre-
viously described [39,40]. The cells were plated and maintained in
culture medium (CM, Neurobasal medium supplemented with B27,
glutamax, and penicillin/streptomycin). Cells were matured for
P18 days prior to use. BoNT was added in 50 ll CM per well and
incubated for the indicated times at 37 C in a humidiﬁed 5% CO2
atmosphere. The cells were lysed in 75 ll of LDS lysis buffer and
analyzed by Western blot using a monoclonal anti-SNAP-25 anti-
body (Synaptic Systems) and densitometry as described previously
[39]. All assays were performed in triplicate.
For the toosendanin inhibition assay, 500 Units of BoNT were
added to pre-warmed stimulation medium (SM: neurobasal med-
ium supplemented with 56 mM KCl and 2.2 mM CaCl2 (Invitrogen
custommedia)) in a total volume of 50 ll per well and incubated at
37 C for 6 min. Cells were washed twice with 100 ll CM followed
by incubation at 37 C, 5% CO2 for 24 h. Toosendanin (1 lM) [38]
was added in CM, 1% DMSO at the indicated times after toxin expo-
sure. All assays were performed in triplicate.
To study the duration of action of BoNT/A1 and A2 in neurons,
RSC cells (400 000 per well) were plated into collagen coated 24-
well plates (BD Biosciences). Five Units BoNT/A1 or A2 was added
in 300 ll CM per well and incubated for 48 h at 37 C, 5% CO2. The
cells were washed 3 with 500 ll CM and incubated at 37 C, 5%
CO2 for 22 weeks with bi-weekly media changes. Cells were har-
vested at the indicated times and analyzed by Western blot as de-
scribed above. All time points were tested in at least duplicate.
2.4. Neuro-2a cells BoNT assay
Neuro-2a cells were grown in Dulbecco’s Modiﬁed Eagles Med-
ium (DMEM) supplemented with non-essential amino acids, 10%
fetal bovine serum, and penicillin/streptomycin. The cells were
seeded into 96-well TPP dishes (MidSci) to 50% conﬂuence and
exposed the following day to the indicated amounts of BoNT/A1
or BoNT/A2 in 50 ll DMEM for 24 h or 48 h. Cells lysates were ana-
lyzed by Western blot as described above. To pre-load cells with
gangliosides, the cells were seeded into a 96-well collagen coated
plate and after 24 h the medium was changed to CM (serum free)
containing 25 lg/ml of GT1b (Sigma). After 24 h, the cells were ex-
posed to BoNT/A1 or BoNT/A2 in 50 ll CM for 24 h or 48 h as indi-
cated and cell lysates were analyzed as above. All assays were
performed in triplicate.
2.5. HCR/A1 and HCR/A2 interactions with rat cortical neurons
Synthetic BoNT/A1, BoNT/A2, and TeNT HC receptor binding do-
mains (HCR) containing a 3xFlag epitope were expressed and puri-
ﬁed as described previously [41]. HCR/A1 and A2 consist of
residues 870–1296 of each BoNT/A subtype, while HCR/T consists
of residues 865–1315 of TeNT. Rat E18-cortical neurons were cul-
tured on poly-D-lysine-coated glass cover slips in Neurobasal Med-
ium with 2 mM glutamine and B27 supplement, for 10–14 days
prior to use.
Binding of HCRs to neurons was examined at 4 C for 60 min
with 40 nM HCR/A1, HCR/A2, or HCR/T in low potassium
(15 mM HEPES, 145 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl,
0.5 mM MgCl, pH 7.4) or high potassium (15 mM HEPES,
95 mM NaCl, 56 mM KCl, 2.2 mM CaCl, 0.5 mM MgCl, pH 7.4)buffer. Entry and trafﬁcking of HCRs in neurons was measured
at 37 C for 5 min in low or high potassium buffer. Cells were
washed with Dulbeccos phosphate buffered saline (DPBS) and
ﬁxed with 4% (w/v) paraformaldehyde in DPBS. Cells were incu-
bated with 150 mM glycine in DPBS, washed with DPBS and
blocked with blocking solution [10% (v/v) normal goat serum,
2.5% (w/v) cold ﬁsh skin gelatin (Sigma), 0.1% Triton-X-100,
and 0.05% Tween-20 in DPBS] for 1 h at RT, followed by incuba-
tion with mouse anti-FLAG M2 antibody (SIGMA, 1:15 000 dilu-
tion) in antibody solution [5% (v/v) normal goat serum, 1% (w/v)
cold ﬁsh skin gelatin, 0.1% Triton-X-100, 0.05% Tween-20 in
DPBS] overnight at 4 C. Cells were washed with DPBS and incu-
bated with goat anti-mouse IgG Alexa568 (Molecular Probes;
1:250 dilution) and alexa 488-cholera toxin B subunit (CTB) as
a surface marker. Co-localization experiments were performed
using rabbit anti-Rab5 antibody (Abcam, 1:1000 dilution) and
guinea pig anti-synaptophysin 1 (Synaptic Systems, 1:2000 dilu-
tion) followed by goat anti-mouse IgG Alexa-568, goat anti-rab-
bit IgG Alexa-488 and goat anti-guinea pig IgG Alexa-633 (1:250
dilution), respectively. Mounting reagent CITIFLUOR AF-3 was
added to the well and average ﬂuorescence and standard devia-
tion from eight random ﬁelds was determined. Images were cap-
tured with a Nikon TE2000 TIRF microscope equipped with a CFI
Plan Apo VC 100X Oil, NA 1.4 type objective. Image analyses
were performed using MetaMorph version 7.0 and ﬁgures were
compiled using Photoshop CS (Adobe). HCR binding to cultured
cells was quantiﬁed by two-tailed Student’s t-test and P values
were calculated using GraphPad Prism 5 software.
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3.1. BoNT/A2 is more potent in neuronal cells than BoNT/A1
The sensitivity of RSC cells to BoNT/A1 has previously been
established [39,40]. Sensitivity of RSC cells to BoNT/A1 and A2
was compared by exposing matured RSC cells to serial dilutions
of BoNT/A1 and A2 for 48 h and 4 h. The sensitivity was consis-
tently higher for BoNT/A2 than A1, with 50% SNAP-25 cleavage
achieved at 0.193 Units of A1 and 0.133 Units of A2 after 48 h
exposure (Fig. 1A) and at 230 Units of A1 and 70 Units of A2 after
4 h exposure (Fig. 1B). These data led to the hypothesis that uptake
of BoNT/A2 into RSC cells may be faster than uptake of BoNT/A1.
3.2. BoNT/A2 enters neuronal cells faster than BoNT/A1
To examine this further, RSC cells were exposed to 150 Units
of each BoNT subtype for 1–6 h and cell lysates were assayed for
SNAP-25 cleavage. SNAP-25 cleavage was observed 1 h earlier
and progressed more rapidly for BoNT/A2 than BoNT/A1
(Fig. 1C).
Toosendanin, a speciﬁc inhibitor that blocks translocation of the
BoNT LC into the cytosol [38], was utilized to further analyze the
entry kinetics of BoNT/A1 and A2 into RSC cells. BoNT/E was used
as a control for this assay, because it enters cells signiﬁcantly fasterFig. 3. Sensitivity of Neuro-2a cells to BoNT/A2 and A1. Cells were expthan BoNT/A1 [42]. To achieve uniform endocytic uptake of the
BoNT subtypes, RSC cells were brieﬂy (6 min) exposed to toxin dur-
ing chemical depolarization, followed by 24 h incubation [42]. Too-
sendanin was added in 30 min intervals. SNAP-25 cleavage was
ﬁrst observed when toosendanin was added 150 min after BoNT/
A1 exposure, whereas the same amount of cleavage was evident
as early as 30 min after BoNT/A2 and BoNT/E exposure (Fig. 2). This
indicates that BoNT/A2 enters cells more rapidly than BoNT/A1.
3.3. Greater cellular toxicity by BoNT/A2 is independent of ganglioside
binding
BoNT/A1 and A2 activity were compared further in the more de-
ﬁned background of the Neuro-2a cell line. Neuro-2a cells express
only the C subtype of the SV2 protein receptor [43] and BoNT/A1
sensitivity is increased dramatically if the cells are pre-loaded with
GT1b gangliosides [44]. The sensitivity of this cell line to BoNT/A1
and A2 was examined after 24 and 48 h exposure with and without
GT1b pre-loading (Fig. 3). BoNT/A2 was about 125-fold (24 h) and
25-fold (48 h) more potent than BoNT/A1 in inducing SNAP-25
cleavage (Fig. 3). When the Neuro-2a cells were pre-loaded with
GT1b, sensitivity to both subtypes was increased dramatically
and similarly. This conﬁrms the increased neurotoxicity of BoNT/
A2 in neuronal cells and indicates that ganglioside binding is not
responsible for that difference.osed to BoNT for 24 h or 48 h with or without GT1b pre-loading.
C.L. Pier et al. / FEBS Letters 585 (2011) 199–206 2033.4. BoNT/A1 and BoNT/A2 have a long duration of activity in neuronal
cells
Duration of BoNT activity in neuronal cells was examined as has
been previously described [42]. RSC cells were exposed to 5 Units
of BoNT/A1 or BoNT/A2 for 48 h followed by removal of allFig. 4. HCR/A1, HCR/A2, and HCR/T binding to neurons. Rat cortical neurons were
incubated with HCRs in low or high potassium buffer at 4 C. Bound HCR was
detected using mouse-a-FLAG IgG. CTB was used as a surface marker. (A)
Representative microscopic image. (B) Quantiﬁed HCRs bound determined as the
ratio of anti-FLAG antibody/CTB staining and coomassie stained gel.extracellular toxin and incubation for 622 weeks. SNAP-25 cleav-
age in cell lysates was assessed every 2–4 weeks. Over 22 weeks
of analysis, SNAP-25 cleavage remained constant at 70%, indicat-
ing no recovery of the cells. Similar exposure of cells with BoNT/E
resulted in complete recovery (detection of only full-length SNAP-
25) within 2 weeks, as has been previously reported [42].
3.5. HCR/A2 enters neurons more efﬁciently than HCR/A1
To further address the mechanism responsible for faster cell en-
try by BoNT/A2, rat cortical neurons were exposed to recombinant
HCR derivatives (HCR/A1, HCR/A2, and HCR/T) at 4 C to measure
intrinsic plasma membrane binding HCR/A1 and HCR/A2 showed
no detectable binding to neurons (Fig. 4) under conditions where
HCR/T (HCR of tetanus toxin) binding was observed, indicatingFig. 5. HCR/A1 and HCR/A2 entry to neurons. HCR/A1 or HCR/A2 were incubated
with rat cortical neurons in low or high potassium buffer for 5 min at 37 C. Bound
HCR (anti-FLAG) and marker proteins (anti-Rab) were detected by immuno
ﬂuorescence. (A) A representative ﬁeld is shown. (B) Fluorescence intensity of the
ratio of anti-FLAG (HCR)/anti-Rab5 as a marker for HCR binding and internalization.
Fig. 6. HCR/A1 and HCR/A2 co-localization with synaptophysin 1 (Physin) and Rab5. HCR/A1 and A2 were incubated with rat cortical neurons in high potassium buffer for
5 min at 37 C. (A) HCR co-localization (FLAG epitope) with synaptophysin 1 and Rab5. (B) Co-localization of HCR/A1 A2 (red) with Rab5 and synaptophysin 1 (green) was
plotted in ﬂuorescence intensities units (arbitrary).
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membrane of neurons. Cell entry and trafﬁcking were measured
by exposure of neurons to HCR/A1 and A2 at 37 C in low and high
potassium buffer to mimic resting and activated neurons, respec-
tively. In low potassium, HCR/A1 and HCR/A2 entry into neurons
was low (Fig. 5) consistent with the need for synaptic vesicle fusion
to expose SV2, the BoNT/A protein receptor, on the plasma mem-
brane. In high potassium, HCR/A1 and HCR/A2 entry were detected
with signiﬁcantly greater amounts of HCR/A2 cell associated rela-
tive to HCR/A1.
To further characterized the pathway that HCR/A utilizes to
enter neurons, co-localization of the HCRs with synaptic vesicle
(synaptophysin 1)- and endocytosis (Rab5)-marker proteins was
measured. In high potassium buffer, HCR/A1 and A2 co-localized
to both marker proteins. Both demonstrate greater co-localization
to the synaptophysin 1 than to Rab5, which is consistent with cell
entry via synaptic vesicle endocytosis (Fig. 6). HCR/A2 showed a
statistically greater amount of co-localization with synaptic vesi-
cles than HCR/A1, indicating that HCR/A2 entered neurons more
efﬁciently than HCR/A1.
4. Discussion
In this study, the biological activity of BoNT/A2 is compared to
BoNT/A1 using neuronal cell models. Exposure of RSC cells andNeuro-2a cells to BoNT/A1 or A2 showed increased sensitivity of
the cells to BoNT/A2 (Figs. 1 and 3), suggesting that the biological
potency of BoNT/A2 is greater than BoNT/A1 in neuronal cells. Pre-
loading Neuro-2a cells with GT1b gangliosides resulted in equally
increased sensitivity to both BoNT/A1 and A2, indicating that the
greater intoxication by BoNT/A2 is independent of ganglioside
binding, which correlates with the high degree of sequence simi-
larity in the gangliosides binding pocket of BoNT/A1 and A2
[21,25].
Studies with toosendanin, a speciﬁc inhibitor of BoNT LC trans-
location [38], indicated that the enhanced neurotoxicity of BoNT/
A2 compared to A1 is due to more rapid translocation of BoNT/
A2 or to a step in the intoxication process preceding translocation
(Fig. 2). A mechanism utilizing faster cell entry rather than in-
creased LC activity is consistent with earlier studies showing that
rLCs of BoNT/A1 and A2 had similar catalytic potentials, a high de-
gree of sequence similarity in the catalytic LC domain and the gan-
glioside binding pocket, and the greatest difference in amino acid
sequence in the protein receptor binding domain [21,25]. BoNT/
A2’s fast cellular entry mandates that for toosendanin to be fully
effective it needs to be used in a prophylactic fashion, whereas
BoNT/A1’s slower cellular entry provides a window of opportunity
for toosendanin to be effective both as a prophylactic and a thera-
peutic. The lack of any SNAP-25 recovery in RSC cells incubated for
up to 22 weeks after BoNT/A1 and A2 exposure indicates that both
C.L. Pier et al. / FEBS Letters 585 (2011) 199–206 205toxin subtypes have a duration of action of at least 22 weeks in cul-
tured neurons.
The mechanism of faster cell entry by BoNT/A2 was further
examined using recombinant heavy chain receptor domains (HCR)
to measure cellular entry and trafﬁcking into primary cortical neu-
rons, a neuronal cell model previously established for similar stud-
ies [45]. The greater amount of cell associated HCR/A2 at 37 C,
relative to HCR/A1, indicated that HCR/A2 possessed a greater
capacity to enter neurons. The unique entry properties of the
BoNT/A subtypes could be explained by differential afﬁnity for
SV2 or a speciﬁc SV2 isotype. Preferential binding of BoNT/A1 to a
SV2-isotypes has previously been observed [46,47]. Other steps that
may account for the differential entry properties of the BoNT/A
subtypes are the rate of entry into synaptic vesicle derived endo-
somes or the rate of translocation of the LC into the cell cytosol.
Taken together, the data presented in this study conﬁrm faster
and increased intoxication of neuronal cells by BoNT/A2 compared
to A1 due to faster cell entry by BoNT/A2, while maintaining
similar longevity of action. These data are consistent with a recent
report suggesting greater potency of BoNT/A2 than A1 in vivo [33].
Future experiments resolving the precise mechanism responsible
for the different entry properties of these BoNT/A subtypes will
provide insight into the mechanism of BoNT/A entry into neurons
and provide information to manipulate the entry properties of
the BoNTs to facilitate their utilization for intervention of neuro-
logical injury, inhibitor design, and enhanced activity as a pharma-
ceutical [3,5,48].
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